Physician profile
Emmanuel Mompi
NPI 1124099742
$8,823.36
in general payments reported to CMS, 2019-2025
31 companies · $2,089 in 2025
The $2,089 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,936 · 2020: $438 · 2021: $942 · 2022: $1,129 · 2023: $1,505 · 2024: $783 · 2025: $2,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,296 · Gift: $81.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,296.28 |
| Gift | $81.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,039.77 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $575.89 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $563.49 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Janssen Scientific Affairs, LLC | $501.70 | 2019-2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $429.73 | 2019-2023 | Ocaliva |
| Braintree Laboratories, INC. | $357.19 | 2019-2024 | Suflave, Sutab |
| Novo Nordisk INC | $264.63 | 2023-2025 | Wegovy |
| Ethicon US, LLC | $249.82 | 2019-2020 | |
| Genzyme Corporation | $244.00 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $234.86 | 2024-2025 | Voquezna |
| Celgene Corporation | $231.32 | 2022-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $224.28 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $210.13 | 2020-2023 | Epclusa |
| Takeda Pharmaceuticals U.S.A., INC. | $191.45 | 2019-2025 | Entyvio |
| Celltrion USA INC. | $146.08 | 2025 | Zymfentra, Vegzelma |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $143.84 | 2023-2025 | Ibsrela |
| Pfizer INC. | $121.60 | 2023-2025 | |
| Boston Scientific Corporation | $119.87 | 2025 | Axios |
| Sanofi-Aventis U.S. LLC | $117.68 | 2025 | |
| Redhill Biopharma INC. | $117.07 | 2022-2024 | Talicia, Aemcolo |
| Merck Sharp & Dohme LLC | $116.01 | 2019 | |
| Ambu INC. | $108.65 | 2022 | |
| Medtronic, INC. | $107.28 | 2022 | |
| Evoke Pharma, INC. | $105.61 | 2021-2022 | |
| Ucb, INC. | $98.25 | 2019 | |
| Madrigal Pharmaceuticals | $84.81 | 2025 | Rezdiffra |
| Intuitive Surgical, INC. | $49.75 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $21.80 | 2022 | |
| Ironwood Pharmaceuticals, INC | $17.24 | 2022 | |
| Nestle Healthcare Nutrition INC. | $16.67 | 2022 | |
| Ferring Pharmaceuticals INC. | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Mompi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.